Aim: To assess the effect of zinc supplements in management of symptomatic benign migratory ‎glossitis patients as a primary outcome and to evaluate levels of salivary zinc before and after ‎treatment as a secondary outcome.‎ Materials and Methods: A randomized controlled clinical and biochemical study was carried out on ‎‎48 patients diagnosed with geographic tongue. Patients were divided equally into two groups; the study ‎group received zinc supplements along with a zinc-rich diet for one month, while the control group ‎was given only a zinc-rich diet for the same duration. Clinical parameters including the size of red ‎atrophic areas (atrophic area length, atrophic area width), and visual analogue scale pain score. Both ‎parameters were recorded at baseline, after one month of treatment and after one month later without ‎treatment. Salivary samples were collected from both groups for biochemical analysis (measuring zinc ‎levels) at baseline and one month after treatment.‎ Results: Reduction in values of atrophic area length (9.88±5.51), atrophic area width (6.5±4.26) in ‎study group compared to (10.88±2.31), (7.38±2.14) respectively in control group, significantly higher ‎median values of   visual analogue scale pain score in control group (5.5), in comparison to study ‎group (3.5), (p=0.004), as well after one month of treatment, the study group exhibited a significantly ‎higher salivary zinc mean value compared to the control group (p=0.045).‎ Conclusion: Low dose of zinc sulphate has a significant therapeutic effect on the relief of subjective ‎symptoms in patients with BMG.‎